| Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044) |
|---|
| 04/18/2002 | US20020045646 Pharmaceutical preparations comprising substituted benzimidazole proton pump inhibitors with fast acting buffer; gastric acid stability for enteral administration |
| 04/18/2002 | US20020045604 Formulations for treating or preventing mucositis |
| 04/18/2002 | US20020045601 Ophthalmic compositions |
| 04/18/2002 | US20020045600 Topical skin treatment for sea lice, insect bites and skin irritation |
| 04/18/2002 | US20020045582 Stabilized protein crystals formulations containing them and methods of making them |
| 04/18/2002 | US20020045571 Reduced-viscosity concentrated protein formulations |
| 04/18/2002 | US20020045263 Biodegradable particles for use in time release agents and gene therapy |
| 04/18/2002 | US20020045004 By reducing the amount of solvent used in the solution, the level of VOCs emission during the coating process also is reduced. Either supercritical carbon dioxide or subcritical carbon dioxide can be used |
| 04/18/2002 | US20020044992 Calcium compound and an acidulant; pH of the composition is from 3.5 to 4.5; having reduced tooth erosion characteristics, especially acid beverages such as fruit juice |
| 04/18/2002 | US20020044991 At least two cores of a multicore structure have a different chemical composition; used to produce food supplements, and as additive to foods, animal feeds, pharmaceutical and cosmetic preparations. |
| 04/18/2002 | US20020044976 Microparticles |
| 04/18/2002 | US20020044975 Colon-specific drug release system |
| 04/18/2002 | US20020044974 Smooth texture; excipient free |
| 04/18/2002 | US20020044973 Microparticles and their use in cancer treatment |
| 04/18/2002 | US20020044971 Delivery vehicle of a solid drug particle within a diffusional boundary layer made up of a matrix and a solubilizing agent |
| 04/18/2002 | US20020044970 Monolayer sugar-coated tablet and process for preparation thereof |
| 04/18/2002 | US20020044969 Method for increasing the compressibility of poorly binding powder materials |
| 04/18/2002 | US20020044967 Sustained release preparations |
| 04/18/2002 | US20020044966 Pharmaceutical formulations containing an opioid and an alpha-agonist |
| 04/18/2002 | US20020044965 Side effect profile reduction |
| 04/18/2002 | US20020044964 Deliver of testosterone to the bloodstream of a mammal through a mucosal surface with polycarbophil and carbopol polymers |
| 04/18/2002 | US20020044962 Encapsulation products for controlled or extended release |
| 04/18/2002 | US20020044961 Nutritional formulations |
| 04/18/2002 | US20020044960 Pharmaceutical, compressible, tableting and lubricating materials; caplet with a diameter and length from 1 to 7 millimeters |
| 04/18/2002 | US20020044959 Biomolecule carrier bearing molecules that bind to a cellular adhesion molecule expressed on endothelial cell |
| 04/18/2002 | US20020044958 Disaccharide protector; frozen; preserved for longer than one year; shows excellent restoration ability in water |
| 04/18/2002 | US20020044956 Microbiocides, antiinflammatories, antihistamines and mucoadhesives |
| 04/18/2002 | US20020044947 Powdered mixture of Hericium, Radix Astragali, Cordyceps Sinensus, Radix Glycyrrhizae and Dioscoreae Oppositae; enhanced production of Interleukin-1 beta without increasing production of Interleukin-4 |
| 04/18/2002 | DE10060550C1 Transdermal therapeutic system for administration of oxybutynin, especially for treatment of bladder dysfunction, having two-phase matrix layer of active agent-containing droplets dispersed in adhesive |
| 04/18/2002 | DE10050382A1 Encapsulating liquid droplets, useful for pharmaceuticals, dyes or plant-protection agents, comprises first forming a polyelectrolyte film at the phase boundary of an emulsion |
| 04/18/2002 | CA2751188A1 Reduced-viscosity concentrated protein formulations |
| 04/18/2002 | CA2425632A1 Agents for the treatment of viral infections |
| 04/18/2002 | CA2425508A1 Targeted therapeutic agents |
| 04/18/2002 | CA2425035A1 Medicinal aerosol formulations |
| 04/18/2002 | CA2424928A1 Encased food product with contrasting components |
| 04/18/2002 | CA2424444A1 Topical antibiotic composition for treatment of eye infection |
| 04/18/2002 | CA2424069A1 Method of forming polypeptide particles |
| 04/18/2002 | CA2424055A1 Medication delivery devices |
| 04/17/2002 | EP1197265A1 Powder material spraying device |
| 04/17/2002 | EP1197222A2 A stabilized pharmaceutical formulation comprising growth hormone and histidine |
| 04/17/2002 | EP1197221A1 Preparations stabilized over long time |
| 04/17/2002 | EP1197217A1 Use of sodium nitroprussiate in obstetrics and gynaecology |
| 04/17/2002 | EP1197215A2 Anthelmintic compositions |
| 04/17/2002 | EP1197212A1 Adhesive preparation for percutaneous absorption |
| 04/17/2002 | EP1197209A1 Percutaneously absorbable preparations |
| 04/17/2002 | EP1197208A1 Sustained release compositions, process for producing the same and use thereof |
| 04/17/2002 | EP1197207A2 Stable compositions for parenteral administration |
| 04/17/2002 | EP1197205A2 Composition for improving cooling sensation effects |
| 04/17/2002 | EP1197201A2 Wax product for hair with non-volatile oils and volatile hydrophobic substances |
| 04/17/2002 | EP1197147A1 Method of inactivating viral particles in a blood product |
| 04/17/2002 | EP1196618A2 Novel vector complexes and their use in gene therapy |
| 04/17/2002 | EP1196495A1 Freeze-dried agent containing paramylon, production and utilization thereof |
| 04/17/2002 | EP1196432A2 FVIIa ANTAGONISTS |
| 04/17/2002 | EP1196431A1 A substantially crystalline form of melagatran |
| 04/17/2002 | EP1196430A2 Purification and stabilization of peptide and proteins in pharmaceutical agents |
| 04/17/2002 | EP1196383A1 Process for preparing amlodipine benzenesulphonate |
| 04/17/2002 | EP1196236A1 Spray drying process for preparing dry powders |
| 04/17/2002 | EP1196211A1 Enhanced thawing of biopharmaceutical solutions using oscillatory motion |
| 04/17/2002 | EP1196197A2 Recombinant parainfluenza virus vaccines attenuated by deletion or ablation of a non-essential gene |
| 04/17/2002 | EP1196195A1 Nasogastric enteral formulations |
| 04/17/2002 | EP1196189A2 Multiple agent diabetes therapy |
| 04/17/2002 | EP1196187A1 Keratinocyte growth factor-2 formulations |
| 04/17/2002 | EP1196183A2 Oregano-based therapeutic composition |
| 04/17/2002 | EP1196175A1 Pharmaceutical tablets |
| 04/17/2002 | EP1196162A1 Procyanidin oligomers for inhibiting matrix metalloproteinases and medicine having effective composition of same |
| 04/17/2002 | EP1196157A1 Amphiphilic drug-oligomer conjugates with hydrolyzable lipophile components and methods for making and using the same |
| 04/17/2002 | EP1196156A2 Transnasal anticonvulsive compositions and modulated process |
| 04/17/2002 | EP1196151A1 Transdermal therapeutic system for administering a calcium antagonist |
| 04/17/2002 | EP1196150A1 Silver-containing, sol-gel derived bioglass compositions |
| 04/17/2002 | EP1196149A1 BIODEGRADABLE POLY(ALKYLENE OXIDE)-POLY(p-DIOXANONE) BLOCK COPOLYMER SOLUBLE IN ORGANIC SOLVENTS, AND DRUG DELIVERY COMPOSITION COMPRISING SAME |
| 04/17/2002 | EP1196148A1 Process for microencapsulation of water soluble substances |
| 04/17/2002 | EP1196147A1 Oral liquid compositions |
| 04/17/2002 | EP1196146A2 Powder particles with smooth surface for use in inhalation therapy |
| 04/17/2002 | EP1196145A1 Methods and apparatus for preparation of lipid vesicles |
| 04/17/2002 | EP1196144A2 A liposome composition having resistance to freeze/thaw damage |
| 04/17/2002 | EP1196143A1 Method for releasing an agent from a red blood cell |
| 04/17/2002 | EP1196141A1 Use of at least one extract of a plant of the genus lannea in a cosmetic or dermopharmaceutical composition |
| 04/17/2002 | EP1196138A1 Pre-formed gel sheet |
| 04/17/2002 | EP1196137A1 Systems comprising organosiloxane resins for delivering oral care substances and for prolonging such delivery |
| 04/17/2002 | EP1196135A1 Compositions comprising organosiloxane resins for delivering oral care substances |
| 04/17/2002 | EP1196043A1 An effervescent green tea extract formulation |
| 04/17/2002 | EP1196034A1 Antiparasitic formulation |
| 04/17/2002 | EP1121145B1 Insulin preparations for pulmonary delivery containing menthol |
| 04/17/2002 | EP1042100B1 Laser beam cutting method for cutting laminates for applying to the skin |
| 04/17/2002 | EP1035834B1 Osmotic dosage form comprising first and second coats |
| 04/17/2002 | EP1033991B1 Mometasone furoate suspensions for nebulization |
| 04/17/2002 | EP1028730B1 Compositions of lipid lowering agents |
| 04/17/2002 | EP1019037B9 Medicament containing delta-aminolevulinic acid |
| 04/17/2002 | EP0994726B1 Compositions suitable for delivery of genes to epithelial cells |
| 04/17/2002 | EP0986404B1 Gene therapy delivery system for targeting to endothelia |
| 04/17/2002 | EP0956010B1 Pharmaceutical microspheres of valproic acid for oral administration |
| 04/17/2002 | EP0948313B1 Use of an extract of gaboon resin in cosmetics and pharmaceutics, in particular for dermatological purposes |
| 04/17/2002 | EP0925293A4 Method of producing an extruded nutritional supplement product |
| 04/17/2002 | EP0914092B1 Microchip drug delivery devices |
| 04/17/2002 | EP0906127B1 Novel devices for transdermal administering of trimegestone |
| 04/17/2002 | EP0902783B1 Hydrolysis-promoting taxane hydrophobic derivatives |
| 04/17/2002 | EP0901378B1 Pharmaceutical compositions containing cyclosporine and a carrier comprising at least an ester of alpha-glycerophosphoric acid |
| 04/17/2002 | EP0889721B1 Remedy for external application, and use of an oil-in-water emulsion for said remedy |
| 04/17/2002 | EP0886652B1 Pulmonary surfactant peptide solubilization process |
| 04/17/2002 | EP0873129B1 Anion exchange resin-containing tablets |